The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8, but not CD4, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the cancer vaccine Ad5-GUCY2C-PADRE was evaluated in a first-in-man phase I clinical study of patients with early-stage colorectal cancer to assess its safety and immunological efficacy.
The colorectal cancer antigen GUCY2C exhibits unique split tolerance, evoking antigen-specific CD8, but not CD4, T-cell responses that deliver anti-tumor immunity without autoimmunity in mice. Here, the cancer vaccine Ad5-GUCY2C-PADRE was evaluated in a first-in-man phase I clinical study of patients with early-stage colorectal cancer to assess its safety and immunological efficacy.